Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
Overview
The purpose of this post-approval study is to evaluate the long-term performance of the GORE TAG® Thoracic Endoprosthesis (TAG device) in the primary treatment of descending thoracic aortic (DTA) aneurysms
Full Title of Study: “A Clinical Evaluation of the GORE TAG Thoracic Endoprosthesis in the Primary Treatment of Descending Thoracic Aortic Aneurysms”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 2013
Interventions
- Device: GORE TAG® Thoracic Endoprosthesis
- implant
Arms, Groups and Cohorts
- Other: GORE TAG® Thoracic Endoprosthesis
Clinical Trial Outcome Measures
Primary Measures
- Aneurysm Related Death
- Time Frame: 5 years
- Freedom from aneurysm related mortality for TAG 05-02 subjects
Secondary Measures
- A Subset of Major Adverse Events Will be Evaluated in Subjects Treated With the TAG Device and Subjects Treated With Open Surgical Repair.
- Time Frame: 5 years
- Proportion of subjects in TAG 05-02 with MAEs
Participating in This Clinical Trial
Inclusion Criteria
1. Descending thoracic aortic aneurysm deemed to warrant surgical repair: 1. Fusiform aneurysm greater than or equal to 2 times diameter of normal adjacent aorta 2. Saccular aneurysm 2. Anatomy meets GORE TAG Thoracic Endoprosthesis specification criteria as indicated in the Instructions for Use (Appendix A) 3. Minimum 2 cm non-aneurysmal segment proximal and distal to the aneurysm • <60 degree angle in the aortic arch may require additional length of non-aneurysmal segment if the arch is included in the treatment segment 4. Life expectancy > 2 years 5. Surgical Candidate
- ASA Class I, II, III, or IV – NYHA Class I, II, III or no heart disease 6. Male or infertile female 7. Minimum 21 years of age 8. Able to comply with protocol requirements 9. Signed Informed Consent Form Exclusion Criteria:
1. 4 mm aortic taper and inability to use devices of different diameters, to compensate for the taper, in the treatment area of the aorta 2. Significant thrombus at the proximal or distal implantation zones 3. Mycotic aneurysm 4. Hemodynamically unstable aneurysm rupture (non-contained aneurysm rupture) 5. Acute or chronic aortic dissection 6. Planned occlusion of the left carotid or celiac arteries 7. "Planned" concomitant surgical procedure (other than left subclavian transposition) or previous major surgery within 30 days 8. Myocardial infarction or cerebral vascular accident within 6 weeks 9. Severe respiratory insufficiency sufficient that precludes open thoracotomy 10. Renal insufficiency (Creatinine > 2.0 mg/dL) with or without dialysis 11. Degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome 12. Participation in another investigational device or drug study within 1 year 13. Documented history of drug abuse within 6 months
Gender Eligibility: All
Minimum Age: 21 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- W.L.Gore & Associates
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Mark Morasch, M.D., Principal Investigator, St. Vincent’s Healthcare, Billings MT
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.